Isolation of amniotic fluid-derived mesenchymal

stem cells by Wouters, G. et al.








1 Cryo-Save Labs, Generaal de Wittelaan19 C-B13. 
B-2800 Mechelen - Belgium
2 Cryo-Save Italia - Roma
3
“ARTEMISIA” Fetal-Maternal Medical Centre, 
Department of Genetics and Molecular Biology, 
Rome, Italy
4
“ARTEMISIA” Fetal-Maternal Medical Centre, 
Department Prenatal Diagnosis, 
Rome, Italy
Reprint requests to: Alvaro Mesoraca
“ARTEMISIA” Fetal-Maternal Medical Centre
Department of Genetics and Molecular Biology, 




Mesenchymal stem cells (MSC) are capable of differen-
tiating into different mesenchymal lineages, including
adipose and connective tissue, bone and cartilage. The
most common source of MSCs for clinical use is human
adult bone marrow. Because the frequency and differen-
tiating capacity of MSCs are decreasing with age, differ-
ent fetal tissues have been studied as an alternative
source for MSCs. Recently, in ‘t Anker et al. (2003) and
Tsai et al. (2004) reported that second-trimester amniot-
ic fluid (AF) is a novel and rich source of fetal MSCs use-
ful for clinical applications. AF contains a heterogeneous
population of cells from fetal origin. The fetal MSCs in
AF are probably deriving from the amnion membrane or
other embryonic and extra-embryonic tissues during the
process of fetal development and growth (in ‘t Anker et
al., 2004). 
Aim of the study
The purpose of this study was to investigate whether we
were able to isolate and cultivate MSC from fresh sec-
ond-trimester amniotic fluid samples. 
Materials and methods
Amniotic fluid was collected from 8 second-trimester
pregnancies (mean gestational age, 16 weeks [range
16-18 weeks]). Four mL of the AF samples were cen-
trifugated for 10 minutes at 300g. Pellets were resus-
pended and cultured in DMEM with low glucose supple-
mented with 15% Fetal bovine serum and antibiotics.
Culture flasks were incubated at 37°C, 5% CO2 and
100% humidity. Medium was changed every 3-4 days
until day 14. At that moment, treatment with trypsin/ED-
TA was applied to detach the cells from the bottom of the
flasks (Passage 0). Cell number and vitality was deter-
mined using a Bürker counting chamber combined with
a trypan blue stain. After cell count, cells were recultured
and further passaged to determine the population dou-
bling level of the AF derived MSCs. Mesenchymal stem
cell characteristics were analysed by flow cytometry us-
ing specific CD73+/CD44+/CD45- cell surface markers.  
Results
6156 ± 9056 (mean ± SD) flat, spindle shaped cells
were found attached to the bottom of the plate after a 14
day culture period out of 4mL of fresh AF (n = 8). The re-
sults varied strongly among the 8 different test samples
(minimum = 2083 cells, maximum = 52083 cells), 1
sample (gestational week 16) could not give any MSC. 
In Passage 1 (after 2 trypsine treatments) 75 ± 11%
(mean ± SD) of the cells showed MSC surface markers
whereas in Passage 2 this percentage increased to 83±
7% (mean ± SD). 
The vitality of the MSCs remained high (>90%) over the
different passages (Fig. 1).
In Figure 2, the doubling levels over the different pas-
sages in time are depicted.
Whereas from passage 0 to passage 1 the MSCs, de-
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Figure 1 - Vitality of AFMSCs.
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rived from the AF, possessed a high expansion potency
with a doubling level of 5.5, this growth rate decreased
drastically to passage 2 with a remaining doubling level
of 0.7 while decreasing futher to the next passage.
After 55 days, the initial population would be doubled 8
times, from 6156 cells at the start to 1.5 x 106 cells.
Conclusion
Amniotic fluid may be an alternative fetal stem cell
source. The expansion potency is extremely high in the
first passage (a doubling level of 5.5 compared with our
findings for umbilical cord and adipose tissue derived
MSCs showing a doubling level of 3). Whereas the
MSCs in these latter tissues keep their growth charac-
teristics in time, the amniotic fluid derived MSCs lose
their expansion potency drastically. Furhter studies are
needed to overcome this problem (e.g. changing media
composition).
Studies for an optimal cryopreservation of amniotic fluid
are undergoing.
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Figure 2 - Doubling population level of AFMSCs.
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